Abstract:Background: Loss-of-function mutations in GDF2 /BMP9 are found in heritable pulmonary arterial hypertension (PAH), suggesting a protective role, while protective or pathogenic effects are found in experimental PAH studies depending on context. The net contribution of BMP9 in PAH thus remains controversial. Hypothesis: BMP9 regulates the secretome of pulmonary microvascular endothelium (PMVEC) to contribute to pulmonary artery smooth muscle cell (PASMC) phenotype modulation. Methods: We tested recombinant BMP9, BMP9/BMP10 trap ALK1-Fc, and BMP9 neutralizing antibody before and after development of pulmonary hypertension (PH) in distinct experimental models. We analyzed the impact of BMP9 on the PMVEC transcriptome, intersection with human and experimental PAH lung transcriptomes, and tested the impact of EC-derived genes on PASMC phenotype and growth. Results: ALK1-Fc and anti-BMP9 prevented or reversed experimental PH administered before or after onset of experimental PH. Recombinant disulfide-linked BMP9 was not protective in SUGEN/Hypoxia (SU-Hx)- or monocrotaline (MCT)-induced experimental PH, in contrast to previous studies using incompletely disulfide-linked BMP9, suggesting dissociated monomers might function as competitive BMP9 antagonists. Consistent with this interpretation, BMP9 upregulated PMVEC genes associated with pulmonary vascular remodeling in experimental and human PAH including CXCL12, IGFBP4, ET-1, VEGF-A, and PDGF-BB. Stimulation of PMVEC with BMP9 induced a contractile phenotype ( CNN1;TAGLN ) in co-cultured PASMC. Administration of ALK1-Fc or anti-BMP9 attenuated expression of several of these growth factors in SU-Hx PH. In experimental PH ALK1-Fc and ACTRIIA-Fc elicited peripheral edema, a phenotype associated with use of ALK1-Fc in human trials. Conclusions: BMP9 contributes to experimental PH by regulating expression of EC-derived molecules modulating PASMC growth and phenotype. In contrast to broad strategies that inhibit BMP9 and BMP10 associated with HHT mimicry in clinical trials and rodent PH models, treatment with anti-BMP9 was well-tolerated. Selective antagonism of BMP9 represents a potential therapeutic strategy for human PAH.

Abstract 16991: Rare Variants in BMP10 Confer Risk of Pulmonary Arterial Hypertension

Identification of a Novel Mutation in the BMPR2 Gene in a Pulmonary Arterial Hypertension Patient Using Next‐generation Sequencing

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population

Germline BMP9 Mutation Causes Idiopathic Pulmonary Arterial Hypertension

A rare homozygous missense GDF2 (BMP9) mutation causing PAH in siblings: Does BMP10 status contribute?

A Novel Mutation in the BMPR2 Gene in Familial Pulmonary Arterial Hypertension

Bone Morphogenetic Protein 9, and Its Genetic Variants Contribute to Susceptibility of Idiopathic Pulmonary Arterial Hypertension

Discovery of BMP10 as a new gene underpinning congenital heart defects

Whole Exome Sequencing of Patients With Heritable and Idiopathic Pulmonary Arterial Hypertension in Central Taiwan

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

Hemodynamic and Clinical Profiles of Pulmonary Arterial Hypertension Patients with GDF2 and BMPR2 Variants

BMPR2 Mutation is a Potential Predisposing Genetic Risk Factor for Congenital Heart Disease Associated Pulmonary Vascular Disease.

SOX17 Loss-of-Function Mutation Underlying Familial Pulmonary Arterial Hypertension.

Abstract 18578: BMP9 Regulates Endothelial Expression of Mediators of Pulmonary Vascular Remodeling

Identification of BMP10 as a Novel Gene Contributing to Dilated Cardiomyopathy

Pulmonary vascular phenotype identified in patients with GDF2 (BMP9) or BMP10 variants: an international multicentre study

Molecular genetic framework underlying pulmonary arterial hypertension

A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report

Imaging Features in BMPR2 Mutation-associated Pulmonary Arterial Hypertension

Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection